We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 03, 2021

Ublituximab Plus Ibrutinib vs Ibrutinib Alone for Patients With Relapsed or Refractory High-Risk CLL

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Ublituximab Plus Ibrutinib Versus Ibrutinib Alone for Patients With Relapsed or Refractory High-Risk Chronic Lymphocytic Leukaemia (GENUINE): A Phase 3, Multicentre, Open-Label, Randomised Trial
Lancet Haematol 2021 Feb 22;[EPub Ahead of Print], JP Sharman, DM Brander, AR Mato, N Ghosh, SJ Schuster, S Kambhampati, JM Burke, F Lansigan, MT Schreeder, SD Lunin, A Zweibach, M Shtivelband, PM Travis, JC Chandler, KS Kolibaba, P Sportelli, HP Miskin, MS Weiss, IW Flinn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading